Prediction function of soluble semaphorin 4D level in acute ST segment elevation myocardial infarction with high thrombosis load
-
摘要:目的 探讨可溶性信号素4D(sSema4D)水平对急性ST段抬高型心肌梗死(STEMI)高血栓负荷的预测作用。方法 选取STEMI确诊患者46例为STEMI组(高血栓负荷患者20例和非高血栓负荷患者26例)，不稳定型心绞痛(UA)患者40例为UA组，同时选取同时间段冠状动脉造影(CAG)阴性患者40例为对照组。测定3组患者血清sSema4D水平，评估sSema4D预测冠状动脉血栓负荷的价值; 分析STEMI患者中血清sSema4D与超敏C反应蛋白(hs-CRP)的相关性。结果 STEMI患者的外周血中sSema4D表达水平高于对照组, STEMI高血栓负荷患者sSema4D表达量高于STEMI非高血栓负荷患者，差异有统计学意义(P < 0.05)。STEMI患者中血清sSema4D与hs-CRP呈正相关(P < 0.05), 相关系数为0.384。结论 在STEMI高血栓负荷患者中sSema4D表达水平较高，可能有一定的预测冠状动脉血栓的价值。Abstract:Objective To investigate the prediction function of soluble semaphorin 4D (sSema4D) level in acute ST segment elevation myocardial infarction (STEMI) with high thrombosis load.Methods A total of 46 patients diagnosed with STEMI were selected as STEMI group (20 patients with high thrombotic load and 26 patients without high thrombotic load), and 40 patients with unstable angina (UA) were selected as UA group. Forty patients with negative coronary angiography (CAG) during the same period were selected as control group. The serum sSema4D levels of patients in three groups were determined, and the value of sSema4D in predicting coronary thrombosis load was evaluated; the correlation between serum sSema4D level and high-sensitivity C-reactive protein (hs-CRP) in STEMI patients was analyzed.Results The expression levels of sSema4D in peripheral blood of STEMI patients were significantly higher than that of the control group, and the expression levels of sSema4D in STEMI patients with high thrombotic load were significantly higher than that of STEMI patients without high thrombotic load (P < 0.05). Serum sSema4D was positively correlated with hs-CRP in STEMI patients (P < 0.05), and the correlation coefficient was 0.384.Conclusion The sSema4D expression levels are higher in STEMI patients with high thrombotic load, which may be of certain value in predicting coronary thrombosis.
-
-
表 1 3组基本资料比较[n(%)](x±s)
M 指标 STEMI组(n=46) UA组(n=40) 对照组(n=40) P值 年龄/岁 67.7±12.5 67.6±9.5 63.1±10.2 0.327 性别 男 32 29 25 0.612 女 14 11 15 吸烟 26(56.5) 25(62.5) 30(75.0) 0.196 糖尿病 10(21.7) 5(12.5) 3(7.5) 0.158 低密度脂蛋白/(mmoL/L) 2.7±1.0 2.5±0.9 2.5±0.9 0.858 高密度脂蛋白/(mmol/L) 1.4±0.6 1.1±0.3 1.3±0.3 0.103 肌酐/(μmoL/L) 77.3±37.8 78.0±32.7 70.2±28.9 0.325 谷丙转氨酶/(U/L) 41.5 21 24.5 0.138 hs-CRR/(mmol/L) 9.67 2.72 0.86 < 0.05 hs-CRR: 超敏C反应蛋白。 
下载: 导出CSV
-
[1] REYNOLDS K, GO A S, LEONG T K, et al. Trends in incidence of hospitalized acute myocardial infarction in the cardiovascular research network (CVRN)[J]. Am J Med, 2017, 130(3): 317-327. doi: 10.1016/j.amjmed.2016.09.014
[2] 胡盛寿, 高润霖, 刘力生, 等. 《中国心血管病报告2018》概要[J]. 中国循环杂志, 2019, 34(3): 209-220. doi: 10.3969/j.issn.1000-3614.2019.03.001 [3] CHEN Y, ZHANG L, LIU W X, et al. VEGF and SEMA4D have synergistic effects on the promotion of angiogenesis in epithelial ovarian cancer[J]. Cell Mol Biol Lett, 2018, 23: 2. doi: 10.1186/s11658-017-0058-9
[4] CHEN T, XU D Z, LI Q, et al. The regulation of Sema4D exodomain shedding by protein kinase A in platelets[J]. Platelets, 2016, 27(7): 673-679. doi: 10.3109/09537104.2016.1154141
[5] MALEKI K T, CORNILLET M, BJÖRKSTRÖM N K. Soluble SEMA4D/CD100: a novel immunoregulator in infectious and inflammatory diseases[J]. Clin Immunol, 2016, 163: 52-59. doi: 10.1016/j.clim.2015.12.012
[6] 匡龙, 赵良平, 尤涛, 等. 血清可溶性信号素4D水平与冠状动脉粥样硬化性心脏病发生的相关性研究[J]. 中国全科医学, 2015, 18(36): 4412-4415. doi: 10.3969/j.issn.1007-9572.2015.36.003 [7] 谢洪祥, 金家贵, 周鹏. 延期支架植入在高血栓负荷急性STEMI患者中的应用[J]. 成都医学院学报, 2017, 12(2): 228-231. https://www.cnki.com.cn/Article/CJFDTOTAL-CDYU201702025.htm [8] CHINESE SOCIETY OF CARDIOLOGY OF CHINESE MEDICAL ASSOCIATION, EDITORIAL BOARD OF CHINESE JOURNAL OF CARDIOLOGY. 2019 Chinese Society of Cardiology (CSC) guidelines for the diagnosis and management of patients with ST-segment elevation myocardial infarction[J]. Zhonghua Xin Xue Guan Bing Za Zhi, 2019, 47(10): 766-783. http://www.ncbi.nlm.nih.gov/pubmed/31648459
[9] KUKLINA E M. Receptor functions of semaphorin 4D[J]. Biochemistry Moscow, 2019, 84(9): 1021-1027. doi: 10.1134/S0006297919090049
[10] LABER A, GADERMAIER E, WALLWITZ J, et al. A high-sensitivity enzyme immunoassay for the quantification of soluble human semaphorin 4D in plasma[J]. Anal Biochem, 2019, 574: 15-22. doi: 10.1016/j.ab.2019.03.004
[11] MASTENBROEK T G, VAN GEFFEN J P, HEEMSKERK J W, et al. Acute and persistent platelet and coagulant activities in atherothrombosis[J]. J Thromb Haemost, 2015, 13(Suppl 1): S272-S280. http://smartsearch.nstl.gov.cn/paper_detail.html?id=9d1ca025bab208f92d52b9d2b79fcdeb
[12] KAWANO H, KOHNO Y, IZUMIDA S, et al. Rivaroxaban therapy resulting in the resolution of right atrial thrombosis resistant to ordinary control with warfarin in a patient with atrial fibrillation[J]. Intern Med, 2015, 54(6): 601-604. doi: 10.2169/internalmedicine.54.3003
[13] XIANG L, YOU T, CHEN J, et al. Serum soluble semaphorin 4D is associated with left atrial diameter in patients with atrial fibrillation[J]. Med Sci Monit, 2015, 21: 2912-2917. doi: 10.12659/MSM.895441
[14] HUANG J, WU S, CAO S, et al. Neutrophil-derived semaphorin 4D induces inflammatory cytokine production of endothelial cells via different plexin receptors in Kawasaki disease[J]. Biomed Res Int, 2020, 2020: 6663291. http://www.researchgate.net/publication/347679496_Neutrophil-Derived_Semaphorin_4D_Induces_Inflammatory_Cytokine_Production_of_Endothelial_Cells_via_Different_Plexin_Receptors_in_Kawasaki_Disease/download
[15] LEI J, FU Y, ZHUANG Y, et al. Sema4D aggravated LPS-induced injury via activation of the MAPK signaling pathway in ATDC5 chondrocytes[J]. Biomed Res Int, 2020, 2020: 8691534. http://www.researchgate.net/publication/340933019_Sema4D_Aggravated_LPS-Induced_Injury_via_Activation_of_the_MAPK_Signaling_Pathway_in_ATDC5_Chondrocytes
[16] KIM J M, LIN C J, STAVRE Z, et al. Osteoblast-osteoclast communication and bone homeostasis[J]. Cells, 2020, 9(9): 2073. doi: 10.3390/cells9092073
[17] LONTOS K, ADAMIK J, TSAGIANNI A, et al. The role of semaphorin 4D in bone remodeling and cancer metastasis[J]. Front Endocrinol: Lausanne, 2018, 9: 322. doi: 10.3389/fendo.2018.00322
[18] WU J H, LI Y N, CHEN A Q, et al. Inhibition of Sema4D/PlexinB1 signaling alleviates vascular dysfunction in diabetic retinopathy[J]. EMBO Mol Med, 2020, 12(2): e10154. doi: 10.15252/emmm.201810154
[19] CREA F, LIUZZO G. Pathogenesis of acute coronary syndromes[J]. J Am Coll Cardiol, 2013, 61(1): 1-11.
[20] DANESE E, MONTAGNANA M. An historical approach to the diagnostic biomarkers of acute coronary syndrome[J]. Ann Transl Med, 2016, 4(10): 194. doi: 10.21037/atm.2016.05.19
计量
- 文章访问数: 246
- HTML全文浏览量: 143
- PDF下载量: 8
苏公网安备 32100302010246号
